Belgian Personal Products Stock News

Solvay (ENXTBR:SOLB) is garnering attention as its advancements in bio-based and recyclable polymer technologies align with France’s fast-evolving market and regulatory push for circular economy solutions. Investors are watching how these initiatives shape long-term value. See our latest analysis for Solvay. Solvay’s recent advances in sustainable polymers come at an interesting time for shareholders, given the stock’s hefty 13.44% decline in share price so far this year. While the 1-year...

Nyxoah SA ( EBR:NYXH ) shareholders should be happy to see the share price up 14% in the last month. But that doesn't...

Cmb.Tech (ENXTBR:CMBT) stock is catching investors’ attention today as recent trading patterns point to shifts in sentiment. Shares have seen mixed returns lately, bringing valuation and future prospects into sharper focus for the market. See our latest analysis for Cmb.Tech. While Cmb.Tech’s share price ticked higher over the past quarter, overall momentum has cooled, with a recent one-year total shareholder return of -41.5%. Investors seem to be weighing past volatility against the...

As the European market navigates a mixed landscape, with the pan-European STOXX Europe 600 Index inching higher amid dovish signals from the U.S. Federal Reserve and easing trade tensions, investors are keenly observing economic indicators like industrial production and labor market dynamics. In this environment, identifying promising small-cap stocks that can withstand volatility and capitalize on emerging opportunities is crucial for enhancing portfolio resilience.

Anheuser-Busch InBev (ENXTBR:ABI) shares have seen their ups and downs over the past few months. Recent price action reflects mixed sentiment from investors. The stock’s movement offers a window into the ongoing debates about value and future growth potential. See our latest analysis for Anheuser-Busch InBev. The latest share price of Anheuser-Busch InBev stands at $52.86, a level that reflects both recent volatility and the broader debate about the company’s long-term trajectory. Momentum...

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...

Key Insights Institutions' substantial holdings in Azelis Group implies that they have significant influence over the...

Warehouses De Pauw (WDP) recently reported earnings for the nine months ended September 30, 2025, posting sales of €335.6 million, up from €284.28 million a year earlier, but net income fell to €246.68 million compared to €306.32 million in the prior period. In addition, Clifford Chance announced it advised on WDP’s inaugural €500 million green senior unsecured bond issuance under its EMTN programme, following a Moody’s upgrade of WDP’s long-term issuer rating to A3 with a stable...

On October 13, 2025, UCB announced that Neurology had published favorable results from a multicenter retrospective chart review study of its investigational pyrimidine nucleoside and/or nucleotide therapy in patients with thymidine kinase 2 deficiency (TK2d), showing that 29% (6 out of 21) of treated individuals experienced reduced need for ventilatory support and most adverse events were mild. An interesting aspect of the study is the potential clinical impact on this rare neuromuscular...

Warehouses De Pauw (ENXTBR:WDP) just posted results for the nine months ending September 2025. Sales climbed compared to last year, while net income and earnings per share slipped during the same stretch. See our latest analysis for Warehouses De Pauw. Warehouses De Pauw’s 8.5% share price return over the last 90 days suggests growing optimism, even though the total shareholder return for the past year has been a more modest 2.1%. In the broader context, recent gains appear to reflect renewed...

UCB (ENXTBR:UCB) just shared results from a multicenter study published in Neurology, highlighting that a new investigational therapy for TK2 deficiency showed some treated patients needed less ventilatory support, with mostly mild side effects. See our latest analysis for UCB. Despite some recent pullbacks, UCB’s share price has surged with a 22.5% gain over the past month and a remarkable 42.2% in the last 90 days. Momentum appears to be on the upswing, and when you look at the long game,...

In the past week, Solvay SA reported a year-over-year drop in second-quarter 2025 earnings, with both underlying net sales and EBITDA affected by difficult market conditions. An interesting development is Solvay's achievement of €29 million in cost savings during the quarter while pressing ahead with rare earth and soda ash projects intended to reinforce its market standing. We'll explore how Solvay's ongoing focus on operational efficiency and cost-saving progress informs its investment...

argenx SE recently presented new data for VYVGART® and its efgartigimod pipeline at the 2025 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and the Myasthenia Gravis Foundation of America (MGFA) Scientific Session in San Francisco. These clinical updates, which include pivotal trial and real-world data across multiple patient subgroups, highlight advances in treating generalized myasthenia gravis and support ongoing innovation in rare neuromuscular...

D'Ieteren Group SA ( EBR:DIE ), is not the largest company out there, but it saw significant share price movement...

For many investors, the main point of stock picking is to generate higher returns than the overall market. But its...

When close to half the companies in Belgium have price-to-earnings ratios (or "P/E's") below 15x, you may consider Elia...

UCB SA ( EBR:UCB ) shares have continued their recent momentum with a 25% gain in the last month alone. Looking back a...

Stock pickers are generally looking for stocks that will outperform the broader market. And the truth is, you can make...

Umicore SA ( EBR:UMI ) shares have had a really impressive month, gaining 25% after a shaky period beforehand. Looking...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Readers hoping to buy Melexis NV ( EBR:MELE ) for its dividend will need to make their move shortly, as the stock is...

In October 2025, Umicore announced it had sold its permanently tied up gold inventories from its Jewelry & Industrial Metals and Precious Metals Refining business units, generating €410 million in net proceeds and a significant after-tax capital gain of €370 million. This move enables Umicore to strengthen its balance sheet and optimize financing costs by shifting to revolving metal leases, increasing financial flexibility while maintaining operational effectiveness. Let's explore how...